There are more than 7000 languages in the world, but we need the be able to read and understand the same document when this is translated. There is a need to find the support of parents from Austria and German-speaking Switzerland to review the translation and linguistic aspects of a questionnaire on achondroplasia.

The largest European population-based epidemiological study on achondroplasia was published with data provided by 28 registries in Europe, with cases reported between 1991-2015.

Beyond Achondroplasia has nearly 2 million views from 207 countries. It was started as a blog in April 2013 and it was done by me only, after work and weekends, until 2017. And since then, fantastic people started to support by volunteering and made it possible the creation of this multilingual platform.

Pfizer announced on the 9th May 2019 that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia and short bowel syndrome (SBS).

One of most relevant events on achondroplasia was held by ALPE Foundation (based in Spain), on the 12,13 and 14th October 2018, bringing together leading healthcare experts in dysplasias, pharmaceutical companies, patient organizations, and more than 500 participants.

Beyond Achondroplasia is now converted into a multilanguage platform, with a new image and structure. We are launching it in English, Spanish, Portuguese and Russian. It will now be easier to find the information you need about achondroplasia.